PALISADE BIO, INC. Long-Term Debt
PALISADE BIO, INC. (PALI) had Long-Term Debt of $0 as of 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2022-03-17
- 2021-12-31: Long-term Debt, Excluding Current Maturities $0.00.
- 2021-09-30: Long-term Debt, Excluding Current Maturities $0.00.
- 2021-06-30: Long-term Debt, Excluding Current Maturities $0.00.
- 2020-12-31: Long-term Debt, Excluding Current Maturities $94.00K.
| Period end | Long-term Debt, Excluding Current Maturities | Long-term Debt, Excluding Current Maturities as first filed |
|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-17 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-23 | |
| 2020-12-31 | $94.00K 10-K · filed 2022-03-17 | |
| 2016-03-31 | $2.55M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $3.38M 10-K · filed 2017-03-23 | $3.39M 10-K · filed 2016-03-14 |
| 2015-09-30 | $4.63M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $5.81M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $6.95M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $8.06M 10-K · filed 2016-03-14 | |
| 2014-09-30 | $2.61M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $3.42M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $4.19M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $4.93M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $5.66M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $6.36M 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $7.04M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $0.00 10-K · filed 2014-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |